#161900

OV-3291

Cat. #161900

OV-3291

Cat. #: 161900

Organism: Human

Tissue: Ovary

Disease: Cancer

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Sauriol, et al. 2020. Cancers(Basel). 8,12(8):2222. PMID: 32784519

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: OV-3291
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Organism: Human
  • Tissue: Ovary
  • Donor: Patient was age 59 at diagnosis with no prior cancer history. Was Stage 3, IIIC Ovarian high-grade serous adenocarcinoma. Specimen was collected in 2007
  • Disease: Cancer
  • Morphology: Stretched spindle-like morphology. Formed spheroids with small, compact cores surrounded by loosely aggregated cells with irregular margin
  • Growth properties: Mixed
  • Crispr: No
  • Description: Epithelial ovarian cancer cell line derived from ascites of patient who was diagnosed with Stage 3 IIIC ovarian high-grade serous adenocarcinoma and who was chemothemotherapy naive at time of sampling.
  • Production details: Ascites were centrifuged and cellular fraction was seeded in 100mm place with OSE medium for 40 days with weekly culture medium replacement
  • Biosafety level: 1

Handling

  • Format: Frozen
  • Growth medium: OSE medium, 10% FBS, 0.5ug/ml apmphotericin B and 50ug/ml gentamycin sulfate
  • Temperature: 37° C
  • Atmosphere: 7% O2 and 5% CO2
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen
  • Cultured in antibiotics: 2.5ug/ml amphotericin B and 50 ug/ml gentamicin
  • Characterisation tests: Whole exome sequencing, Gene expression microarray, IHC, Western Blot, etc.
  • Str profiling: TH01: 9 / D21S11: 28,30 / D5S818: 11,12 / D13S317: 9 / D7S820: 8,10 / D16S539: 11 / CSF1PO: 11,12 / vWA: 17 / TPOX: 11 / AMEL: X

References

  • Meng, et al. 2023. J Anim Sci. 3, 101:skad215. PMID: 37351870
  • Borzdzi?owska, et al. 2022. Biomedicines. 11, 10(5):1116. PMID: 35625852